Randomized Phase 3 Study of MRTX849 ['an orally-available, mutationselective small molecule covalent inhibitor of KRAS G12C] in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
